Search Results
Jun 10, 2026, 11:49 ET The Space Economy Just Got an On-Ramp to Wall Street
reported and subject to final pricing): https://capital.com/en-int/learn/ipo/spacex-ipo[4] Bloomberg — "How SpaceX's Dream of a Record-Breaking IPO Stacks Up" (raise reported up to ~$75B; valuation in the trillions;
More news about: Baystreet
Jun 10, 2026, 02:22 ET Lundbeck to present new patient data on neuroendocrine and neuroimmunology programs at ENDO 2026
Lancet. 2015;386(9996):913–927Sharma ST, Nieman LK, Feelders RA. Pituitary. 2015;18(2):188–194Ots HD, Tracz JA, Vinokuroff KE, et al. Int J Mol Sci. 2022;23(8):4115Dhaliwal NK, Razzaq L. Cureus. 2025;17(6):e86483.Lundbeck. Data on fileFeldhaus AL, et al. Endocrinology
More news about: H. Lundbeck A/S
Jun 10, 2026, 02:19 ET Lundbeck to present new patient data on neuroendocrine and neuroimmunology programs at ENDO 2026
Lancet. 2015;386(9996):913–927Sharma ST, Nieman LK, Feelders RA. Pituitary. 2015;18(2):188–194Ots HD, Tracz JA, Vinokuroff KE, et al. Int J Mol Sci. 2022;23(8):4115Dhaliwal NK, Razzaq L. Cureus. 2025;17(6):e86483.Lundbeck. Data on fileFeldhaus AL, et al. Endocrinology
More news about: H. Lundbeck A/S
Jun 09, 2026, 10:01 ET Alcohol-associated Liver Disease Market Gearing Up for Outstanding Expansion at a CAGR of 31.1% During the Forecast Period (2026-2036) | DelveInsight
ALD.Nterica's INT-787 is a next-generation oral farnesoid X receptor (FXR) agonist that was initially developed by Intercept Pharmaceuticals and later integrated into Alfasigma's liver disease portfolio following the company's 2023 acquisition. Through FXR activation, INT-787 is designed to
More news about: DelveInsight Business Research, LLP
Jun 05, 2026, 10:00 ET Eratrectinib, the next-generation TRK inhibitor independently developed by Vcare PharmaTech, has received marketing approval
Feb;11(2):355-372.Cocco E, et al. Nat Rev Clin Oncol. 2018 Dec;15(12):731-747.O'Haire S, et al. Sci Rep. 2023 Mar 13;13(1):4116.Qi C, et al. Int J Cancer. 2023 Dec 1;153(11):1916-1927.Vcare Pharma. Phase II Clinical Study Data of Eratrectinib[R]Commercial Cooperation:Strategic
More news about: Vcare PharmaTech
Jun 04, 2026, 08:00 ET HawkEye 360 Announces Two Key Leadership Appointments
company's continued growth and operational scale."Alex brings extraordinary systems engineering experience across space, airborne, and multi-INT domains, while EJ has played an instrumental role in building and advancing HawkEye 360's engineering foundation," said Todd Probert, Chief Operating
More news about: HawkEye 360 Inc.
Jun 03, 2026, 17:44 ET Red Bull Basement ayuda a emprendedores a convertir su idea en una empresa emergente financiada
para medios: redbull.com/int-en/events/red-bull-basement-world-final-2026Contacto para medios: [email protected]:
More news about: Red Bull
Jun 03, 2026, 13:45 ET Red Bull Basement hilft Gründern dabei, ihre Idee in ein finanziertes Start-up zu verwandeln
für Medien: redbull.com/int-de/events/red-bull-basement-world-final-2026Medienkontakt: [email protected]:
More news about: Red Bull
Jun 03, 2026, 13:41 ET Red Bull Basement aide les fondateurs à exploiter le potentiel de la programmation intuitive pour transformer leur idée en jeune pousse financée
médias : redbull.com/int-fr/events/red-bull-basement-world-final-2026Relations avec les médias : [email protected] :
More news about: Red Bull
Jun 03, 2026, 09:46 ET Axi 推出《Trading Triumphs》：輝煌背後，交易者榮獲 Axi Select 資助的故事
的故事揭開序幕。閱覽並收看閱覽完整網誌：https://www.axi.com/int/blog/company-news/axi-select-trading-triumphs-yoleny 收看 Yoleny 的故事：
More news about: AxiTrader LLC
Jun 03, 2026, 06:01 ET Axi lança "Trading Triumphs": As histórias dos traders que conquistaram o financiamento do Axi Select
https://www.axi.com/int/blog/company-news/axi-select-trading-triumphs-yoleny Assista à história de Yoleny:
More news about: AxiTrader LLC
Jun 03, 2026, 05:54 ET Axi lança "Trading Triumphs": As histórias dos traders que conquistaram o financiamento do Axi Select
https://www.axi.com/int/blog/company-news/axi-select-trading-triumphs-yoleny Assista à história de Yoleny:
More news about: AxiTrader LLC
Jun 03, 2026, 04:12 ET Red Bull Basement Is Helping Founders Vibe Code Their Idea Into a Funded Startup Reality
for media: redbull.com/int-en/events/red-bull-basement-world-final-2026Media Contact: [email protected]:
More news about: Red Bull
Jun 03, 2026, 04:10 ET Axi präsentiert Trading Triumphs: Die Geschichten hinter den Tradern, die sich ihre Axi Select-Finanzierung verdient haben
https://www.axi.com/int/blog/company-news/axi-select-trading-triumphs-yoleny Sehen Sie sich die Geschichte von Yoleny an:
More news about: AxiTrader LLC
Jun 03, 2026, 04:02 ET Axi、「Trading Triumphs」を開始：Axi Selectで資金提供を受ける権利を獲得したトレーダーたちの物語
記事を読む・動画を見るブログ記事全文を読む：https://www.axi.com/int/blog/company-news/axi-select-trading-triumphs-yolenyYolenyのストーリーを見る
More news about: AxiTrader LLC
Jun 03, 2026, 04:00 ET Red Bull Basement Is Helping Founders Vibe Code Their Idea Into a Funded Startup Reality
for media: redbull.com/int-en/events/red-bull-basement-world-final-2026Media Contact: [email protected]:
More news about: Red Bull
Jun 03, 2026, 03:58 ET 액시, Trading Triumphs 출시: Axi Select 펀딩 획득한 트레이더들의 비하인드 스토리
https://www.axi.com/int/blog/company-news/axi-select-trading-triumphs-yoleny욜레니의 이야기 보기:https://youtu.be/JTieJWQqrzA?si=qANS5rOlgL7EiidTAxi
More news about: AxiTrader LLC
Jun 02, 2026, 18:15 ET Axi lance « Trading Triumphs » : Les histoires des traders qui ont obtenu un financement Axi Select
https://www.axi.com/int/blog/company-news/axi-select-trading-triumphs-yoleny Regardez l'histoire de Yoleny :
More news about: AxiTrader LLC
Jun 02, 2026, 11:20 ET Axi presenta Trading Triumphs: los operadores que consiguieron financiación a través de Axi Select
https://www.axi.com/int/blog/company-news/axi-select-trading-triumphs-yolenyVea la historia de Yoleny:
More news about: AxiTrader LLC
Jun 02, 2026, 07:18 ET Axi Launches Trading Triumphs: The Stories Behind the Traders Who Earned Their Axi Select Funding
https://www.axi.com/int/blog/company-news/axi-select-trading-triumphs-yoleny Watch Yoleny's story:
More news about: AxiTrader LLC
Jun 02, 2026, 07:11 ET Axi Launches Trading Triumphs: The Stories Behind the Traders Who Earned Their Axi Select Funding
https://www.axi.com/int/blog/company-news/axi-select-trading-triumphs-yoleny Watch Yoleny's story:
More news about: AxiTrader LLC
Jun 01, 2026, 04:19 ET Sobi to present new data on pegcetacoplan at ERA 2026
here.References1. Smith RJH, et al. Nat Rev Nephrol. 2019;15(3):129-143. 2. Servais A, et al. Kidney Int. 2012;82(4):454-464.3. Zand L, et al. J Am Soc Nephrol. 2014;25(5):1110-1117.4. Tarragón, B, et al. Clin J Am Soc Nephrol 2024; 19(8)1005-1015.5.
More news about: Swedish Orphan Biotrauma AB
Jun 01, 2026, 03:04 ET China's Original Innovative Drug Cipepofol Approved for Marketing by the U.S. FDA
2025;14.9(IF).Yu Y, Deng J, Yin Y,et al. Ciprofol vs propofol for gastrointestinal endoscopy sedation: a systematic review and meta-analysis. Int J Surg. 2025;10.1(IF).He ZZ, Liang JY, Duan JX, et al. Ciprofol versus propofol sedation in ICU patients and norepinephrine requirements: a
More news about: Haisco
May 31, 2026, 08:27 ET Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
10.1200/JCO.2024.42.16_suppl.5026 Stattin P, et al. Population-based study of disease trajectory after radical treatment for high-risk prostate cancer. BJU Int. 2024;134:96-102. doi.org/10.1111/bju.163627 National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology:
More news about: Johnson & Johnson
May 30, 2026, 08:05 ET ROADS Phase 3 Clinical Trial Data Presented at ASCO26 Show GammaTile® Provides Superior Tumor Control Leading to Patients Living Longer Without Recurrence Compared to Standard of Care in Newly Diagnosed Operable Brain Metastases
2025;11(8):890–899.Brennan C, Yang TJ, Hilden P, et al. A phase 2 trial of stereotactic radiosurgery boost after surgical resection for brain metastases. Int J Radiat Oncol Biol Phys. 2014;88:130–136.Garcia MA, Turner A, Brachman DG. The role of GammaTile in the treatment of brain tumors: a technical
More news about: GT Medical Technologies